Cited by 946PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 178 of the 180 references it cites were found in a registry or an index.

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Open access

Konstantinopoulos, Panagiotis A., Ceccaldi, Raphael, Shapiro, Geoffrey I., D'Andrea, Alan D.·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-15-0714PMC PMC4631624

Open this paper in CoChat — free account

Abstract

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes. Defective HR is an important therapeutic target in EOC as exemplified by the efficacy of platinum analogues in this disease, as well as the advent of PARP inhibitors, which exhibit synthetic lethality when applied to HR-deficient cells. Here, we describe the genotypic and phenotypic characteristics of HR-deficient EOCs, discuss current and emerging approaches for targeting these tumors, and present challenges associated with these approaches, focusing on development and overcoming resistance. Significance: Defective DNA repair via HR is a pivotal vulnerability of EOC, particularly of the high-grade serous histologic subtype. Targeting defective HR offers the unique opportunity of exploiting molecular differences between tumor and normal cells, thereby inducing cancer-specific synthetic lethality; the promise and challenges of these approaches in ovarian cancer are discussed in this review. Cancer Discov; 5(11); 1137–54. ©2015 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-0714

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

Show all 180 references

Sorted by citations

Items 601–700 of 946

Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?
Lee, M. S., & Kopetz, S. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab170 · Cited by 6
Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
Zhang, Y., Xu, M., Yuan, J., Hu, Z., Jiang, J., Sun, Y., Huang, J. S., Wang, Y., Wang, B., Shen, J., et al. (2024) · eLife · doi:10.7554/elife.99225 · Cited by 8
Homologous Recombination Proficiency in High-Grade Serous Epithelial Ovarian Cancer Tumors: The Dark Side of the Moon
Pavanello, M., Vieira, C. M., Arenhardt, M. P., & Nogueira‐Rodrigues, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090702 · Cited by 5
Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Pradhan, B., Oikkonen, J., Zhang, K., Botto, J. M., Eriksson, M. R., Sundaresan, S., Genç, F., Pisanic, T. R., Falco, M. M., Li, Y., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4419 · Cited by 5
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer
Duffield, J. R., Hou, X., Wilson, B. W., Prasad, A., McKeon-Makki, I. K., Huehls, A. M., Wu, X., Correia, C., Larson, M. C., Couch, F. J., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adt8706 · Cited by 5
Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: implications for a precision treatment approach
Pham, A. T., Yuan, F., Nagathihalli, N. S., & Dosch, A. R. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101309 · Cited by 5
Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO
Heublein, S., Baum, J., Jaeger, A., Grimm, D., Olthoff, J., Braicu, E. I., Nieto, O. A., Haßdenteufel, K., Schmalfeldt, B., Hanker, L., et al. (2023) · Cancers · doi:10.3390/cancers15072038 · Cited by 5
Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer
Abujamous, L., Soltani, A., Al-Thawadi, H., & Agouni, A. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9757 · Cited by 5
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe
Moore, K. N., Mirza, M. R., Gourley, C., Pignata, S., Lorusso, D., Monk, B. J., Sehouli, J., Schilder, J. M., D’Esquermes, N., & González-Martı́n, A. (2024) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2024-005405 · Cited by 5
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors
Venkatachalam, A., Correia, C., Peterson, K. L., Hou, X., Schneider, P. A., Strathman, A. R., Flatten, K. S., Sine, C. C., Balczewski, E. A., McGehee, C. D., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02125-5 · Cited by 5
Revisiting Genomic Instability, Tumor Microenvironment and Immune Response in High-Grade Serous Ovarian Cancer
Ratz, L., Baek, S., & Panier, S. (2025) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2613-0489 · Cited by 5
Advancements in nanotechnology for PARP inhibitor delivery: a comprehensive review of diverse nanosystems, their mechanisms, and therapeutic applications across cancer and beyond
Abualsoud, B. M., Alhomrani, M., Alamri, A. S., Alsanie, W. F., Ballal, S., Sharma, G. C., Krithiga, T., Singh, A., Kumar, A., & Deepak, A. (2025) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2025.2534698 · Cited by 5
Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition
Li, Q., Zhang, S., Wang, M., Yi, Q., Xu, H., Wang, J., & Yang, Z. (2025) · Oncogene · doi:10.1038/s41388-025-03522-w · Cited by 5
The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis
Xing, L., Mi, W., Zhang, Y., Tian, S., Zhang, Y., Qi, R., Zhang, C., & Lou, G. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15567 · Cited by 5
Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma
Goebel, E. A., Kerkhof, J., Dzyubak, O., McLachlin, C. M., McGee, J., & Sadiković, B. (2022) · Genes · doi:10.3390/genes13081398 · Cited by 5
Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials
Zhang, Y., Zhang, L., Zhao, Y., Wang, S., & Feng, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.945867 · Cited by 5
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy
Geerinckx, B., Teuwen, L.-A. M. N., Foo, T., Vandamme, T., Smith, A., Peeters, M., & Price, T. J. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2270161 · Cited by 5
VDX‐111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression
Persenaire, C., Babbs, B. L., Yamamoto, T. M., Nebbia, M., Jordan, K. R., Adams, S. F., Lambert, J. R., & Bitler, B. G. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23721 · Cited by 5
AKAP8 promotes ovarian cancer progression and antagonizes PARP inhibitor sensitivity through regulating hnRNPUL1 transcription
Mobet, Y., Wang, H., Wei, Q., Liu, X., Yang, D., Zhao, H., Yu, Y., Ngane, R. A. N., Souopgui, J., Xu, J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109744 · Cited by 5
A Predictive Model for Initial Platinum‐Based Chemotherapy Efficacy in Patients with Postoperative Epithelial Ovarian Cancer Using Tissue‐Derived Small Extracellular Vesicles
Shen, S., Wang, C., Gu, J., Song, F., Wu, X., Qian, F., Chen, X., Wang, L., Peng, Q., Xing, Z., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12486 · Cited by 5
Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research
Nicolini, A., Ferrari, P., Silvestri, R., & Bini, D. A. (2025) · MedComm · doi:10.1002/mco2.70373 · Cited by 5
Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients.
Zimmermann, M. T., Jiang, G., & Wang, C. (2016) · PubMed Central · Cited by 5
Poly adenosine diphosphate-ribosylation, a promising target for colorectal cancer treatment
Jeong, K., & Park, M. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i6.574 · Cited by 5
Homologous Recombination Deficiency and Molecular Subtype are Associated with Immunogenicity in Ovarian Cancer
Fares, C. M., Fenerty, K. E., Chander, C., Theisen, M. K., & Konecny, G. E. (2022) · Biomarkers in Medicine · doi:10.2217/bmm-2022-0044 · Cited by 5
Analytical Principles of Cancer Next Generation Sequencing
Gindin, T. S., & Hsiao, S. J. (2022) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2022.04.003 · Cited by 5
RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma
Kim, K., Kim, S. H., Lee, J., Kim, Y., Lee, S., & Park, E. (2023) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2023.34.e45 · Cited by 5
Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair
Ganzinelli, M., Guffanti, F., Ianza, A., Sobhani, N., Crovella, S., Zanconati, F., Bottin, C., Confalonieri, M., Fumagalli, S., Guglielmi, A., et al. (2023) · Cancers · doi:10.3390/cancers15174309 · Cited by 5
Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background
Chiappa, M., Guffanti, F., Grasselli, C., Panini, N., Corbelli, A., Fiordaliso, F., & Damia, G. L. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053049 · Cited by 5
BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists
Kwong, A., Cheng, K. D., Hsue, C. V., Hui, S. K., Leung, C. R., Leung, K. A., Ngan, K. R., & Soong, S. I. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13116 · Cited by 5
Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents
He, G., Xie, X., & Siddik, Z. H. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04085-1 · Cited by 5
Variants of the human RAD52 gene confer defects in ionizing radiation resistance and homologous recombination repair in budding yeast
Clear, A. D., Manthey, G. M., Lewis, O., Lopez, I. Y., Rico, R., Owens, S. N., Negritto, M. C., Wolf, E. W., Xu, J. Z., Kenjić, N., et al. (2020) · Microbial Cell · doi:10.15698/mic2020.10.732 · Cited by 5
Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers
Tang, Y., Lin, C., & Lai, C. (2021) · Genes · doi:10.3390/genes12101593 · Cited by 5
Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology
Kramer, C. J. H., Vreeswijk, M. P. G., Thijssen, B., Bosse, T., & Wesseling, J. (2022) · The Journal of Pathology · doi:10.1002/path.5915 · Cited by 5
Healthcare professionals’ perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups
Witjes, V. M., Braspenning, J. C. C., Hoogerbrugge, N., Smolders, Y. H. C. M., Hermkens, D. M. A., Mourits, M. J. E., Ligtenberg, M. J. L., Ausems, M. G. E. M., & de Hullu, J. A. (2022) · Familial Cancer · doi:10.1007/s10689-022-00294-0 · Cited by 5
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
Sveen, A., Johannessen, B., Klokkerud, S. M. K., Kraggerud, S. M., Meza‐Zepeda, L. A., Bjørnslett, M., Bischof, K., Myklebost, O., Taskén, K., Skotheim, R. I., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.170423 · Cited by 4
Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study
Nagao, S., Nishio, S., Takehara, K., Sato, S., Satoh, T., Shimada, M., Yamaguchi, S., Tanabe, H., Takano, M., Horie, K., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02585-1 · Cited by 4
Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches
Nakatsuka, E., Tan, L., Cunneen, B. P., Foster, C., Lei, Y. L., & McLean, K. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102119 · Cited by 4
Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey
Banerjee, S. N., Eskander, R. N., Bailey, T., Ambler, W., Volpe, S. V., Özgören, O., Grabowski, J., & Valabrega, G. (2025) · Future Oncology · doi:10.1080/14796694.2025.2449782 · Cited by 4
Pathogenic Germline Variants Among Women with Uterine Cancer by Ancestry: A Commercial Laboratory Collaborative Research Registry Study
Johnson, C. A., Aryasomayajula, C., Francoeur, A., Stewart, C. E., Sia, T., Darcy, K. M., Tian, C., Kapp, D. S., Liu, Y. L., & Chan, J. K. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.04.585 · Cited by 4
HR eye & MMR eye: one-day assessment of DNA repair-defective tumors eligible for targeted therapy
Saito, S., Kato, S., Arai, U., En, A., Tsunezumi, J., Mizushima, T., Tateishi, K., & Adachi, N. (2025) · Nature Communications · doi:10.1038/s41467-025-59462-2 · Cited by 4
CEBPB regulates ERK1/2 activity through SOS1 and contributes to ovarian cancer progression
Tan, J., Wang, D., Tu, A., Xu, Q., Zhuan, L., Wu, X., Lin, Z., Dong, W., Zhang, J., & Feng, Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02794-2 · Cited by 4
PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer
Xi, Q., Kunita, A., Ogawa, M., Kawakami, M., Ka, M., Nagai, S., Duong, A. Q., Taguchi, A., Watanabe, K., Fukuda, T., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08324-2 · Cited by 4
Targeting ZDHHC12-mediated PARP1 palmitoylation potentiates PARP inhibitor cytotoxicity
Zhang, X., Liu, Y., Liao, X., Wang, M., Liu, J., Wen, Y., Liu, R., Sang, X., Li, G., Liu, P., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116910 · Cited by 4
Expanding the therapeutic applications of PARP inhibitors in cancer by targeting receptor tyrosine kinases
Jafari, A., Fathi, S., Moosavi, F., & Firuzi, O. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189552 · Cited by 4
Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer
Prasad, A., Kaufmann, S. H., & Kanakkanthara, A. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189570 · Cited by 4
Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice
Heidinger, M., Caruso, G., Coelho, R., Stiegeler, N., Petousis, S., Kacperczyk-Bartnik, J. P., Oseledchyk, A., Jacob, F., Kurzeder, C., Heinzelmann-Schwarz, V. A., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105312 · Cited by 4
Folate receptor-α targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies
Singh, B., Singh, D., Sah, A., Kumari, P., Kumar, D., & Sharma, D. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117042 · Cited by 4
DNA double-strand repair by nonhomologous end joining and its clinical relevance
Setton, J. S., Bindra, R. S., & Powell, S. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00009-7 · Cited by 4
BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models
Guffanti, F., Mengoli, I., Alvisi, M. F., Dellavedova, G., Giavazzi, R., Fruscio, R., Rulli, E., & Damia, G. L. M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1390116 · Cited by 4
Constitutional BRCA1 Epimutations: A Key for Understanding Basal‐Like Breast and High‐Grade Serous Ovarian Cancer
Lønning, P. E., Nikolaienko, O., & Knappskog, S. (2024) · Human Mutation · doi:10.1155/2024/7353984 · Cited by 4
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?: Lessons From the PAOLA-1/ENGOT-ov25 Trial, a GINECO Study
Kime, A., Bataillon, G., Treilleux, I., Callens, C., Selle, F., Heitz, F., Cinieri, S., González-Martı́n, A., Schauer, C., Lindahl, G., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2024-0081-oa · Cited by 4
Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation
Jia, X., Zhao, S., Li, X., Lv, L., Chen, X., Pan, E., Ou, Q., Song, C., Sun, S., Zhao, J., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s334847 · Cited by 4
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition
D’Ambrosio, C., Erriquez, J., Capellero, S., Cignetto, S., Alvaro, M., Ciamporcero, E. S., Renzo, M. F. D., Perera, T. P. S., Valabrega, G., & Olivero, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105770 · Cited by 4
Potential Targeted Therapies in Ovarian Cancer
Sisman, Y., Vestergaard, L. K., Oliveira, D. V. N. P., Poulsen, T. S., Schnack, T. H., Høgdall, C. K., & Høgdall, E. V. S. (2022) · Pharmaceuticals · doi:10.3390/ph15111324 · Cited by 4
Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Levine, M. D., O’Malley, D. M., Haight, P. J., Senter, L. A., Wagner, V. M., Bixel, K. L., Cohn, D. E., Copeland, L. J., Cosgrove, C. M., McLaughlin, E. M., et al. (2023) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2023.101173 · Cited by 4
Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
Chen, X., Pan, Y., Wang, Q., Ren, C., Li, M., Hao, X., Xie, L., & Liu, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1225033 · Cited by 4
Molecular Pathology of Ovarian Epithelial Neoplasms
Ordulu, Z., Watkins, J. C., & Ritterhouse, L. L. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.004 · Cited by 4
Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors
Snyder, L. A., Damle, R. N., Patel, S. R., Bohrer, J., Fiorella, A., Driscoll, J., Hawkins, R., Stratton, C. F., Manning, C. D., Tatikola, K., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0798 · Cited by 4
Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion
Vergote, I. B., Denys, H. G., Altıntaş, S., Kerger, J. N., Baurain, J. F., Bours, V., Henry, S., de Vijver, K. K. V., Lambrechts, D., & Gennigens, C. (2022) · Facts Views and Vision in ObGyn · doi:10.52054/fvvo.14.2.024 · Cited by 4
HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Khella, C. A., Franciosa, L., Rodrı́guez-Rodrı́guez, L., Rajkarnikar, R., Mythreye, K., & Gatza, M. L. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0496 · Cited by 4
Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation
Sahajpal, N., Mondal, A. K., Vashisht, A., Singh, H., Pang, A. W. C., Saul, D., Omar, N., Hilton, B., DuPont, B. R., Kota, V. K., et al. (2023) · Genes · doi:10.3390/genes14091683 · Cited by 4
Serum Creatinine Elevation as a Risk Factor for Niraparib-induced Hematologic Toxicity
Hashimoto, K., Kawakami, K., Yokokawa, T., SHIBATA, N., Soejima, A., Sugisaki, T., Mori, Y., Shimizu, H., Yunokawa, M., Kanao, H., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16647 · Cited by 4
Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials
Mustafa, M. T., Abushanab, A. K., Mousa, M. T., Qawaqzeh, R. A., Alakhras, H. M., Othman, A. S., & Saed, A. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2309177 · Cited by 4
Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Duma, N., Gast, K. C., Choong, G. M. Y., Leon-Ferre, R. A., & O'Sullivan, C. C. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0709-7 · Cited by 4
Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer
Liu, X., Yang, H., Wu, X., Huang, K., Ma, P., Jiang, P., Zheng, W., Tang, T., & Liu, D. (2019) · Oncology Letters · doi:10.3892/ol.2019.10607 · Cited by 4
Comparative transcriptomic study on the ovarian cancer between chicken and human
Zhu, G., Wang, X., Wang, Y., Huang, T., Zhang, X., He, J., Shi, N., Chen, J., Zhang, J., Zhang, M., et al. (2024) · Poultry Science · doi:10.1016/j.psj.2024.104021 · Cited by 3
Metastatic malignant cylindroma arising on a background of digenic inheritance of BRCA2 and CYLD pathogenic variants targeted with PARP inhibition
Fostier, W., Husain, A., Namini, S., Mathew, B., Holt, G., Memari, Y., Davies, H. R., Koh, C. C., Nik‐Zainal, S., & Rajan, N. (2025) · Clinical and Experimental Dermatology · doi:10.1093/ced/llaf064 · Cited by 3
Homologous recombination deficiency test validation in patients with high-grade advanced ovarian cancer
Rodrigues, A. N., Souto, A. K. D. B. A., de Andrade, D. A. P., Gomes, L. M., Koide, S. S., Silva, R. D. G. E., de Souza, B. B., Massaro, J. D., de Melo, A. C., Borges, A. M., et al. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1524594 · Cited by 3
Role of KLF5 in enhancing ovarian cancer stemness and PARPi resistance: mechanisms and therapeutic targeting
Xiao, H., Cheng, G., Zhang, H., Liu, Y., Chen, Z., Gao, Y., Gao, F., Liu, Y., Wang, S., & Kong, B. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06502-6 · Cited by 3
Big data analysis reveals miR-874 as a suppressor and therapeutic target in the progression from endometriosis to ovarian cancer
Lin, P., Wu, L., Lai, X., Xiao, C., & Ye, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-03587-9 · Cited by 3
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy
Powell, M. A., Ghamande, S. A., Hanker, L. C., Black, D., Raaschou‐Jensen, N., Gilbert, L., Cibula, D., Secord, A. A., Oaknin, A., Holloway, R. W., et al. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.104774 · Cited by 3
Inactivation of VRK1 sensitizes ovarian cancer to PARP inhibition through regulating DNA-PK stability
Kim, D. Y., Yun, H., You, J.-E., Lee, J.-U., Kang, D., Ryu, Y. S., Koh, D., & Jin, D. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114036 · Cited by 3
Structure-specific nucleases in genome dynamics and strategies for targeting cancers
Sun, H., Luo, M., Zhou, M., Zheng, L., Li, H., Esworthy, R. S., & Shen, B. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae019 · Cited by 3
Pan-Cancer Molecular Biomarkers
Dong, F. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.013 · Cited by 3
Revisiting the molecular landscape of Rosai-Dorfman disease: insights from whole exome sequencing of Saudi patients
Binhassan, S., Samman, M. M., Al‐Sheikh, Y. A., Alshakweer, W., Alhalouly, T., Alshamlan, N., & Abudawood, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1556830 · Cited by 3
Navigating PARP Inhibitor Resistance in Ovarian Cancer: Bridging Mechanistic Insights To Clinical Translation
Wang, Z., Liu, Y., & Yang, Q. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01347-z · Cited by 3
T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma
Kim, J.-W., Kim, S., Yang, S.-Y., Joung, J., & Hwang, S. (2023) · Genes · doi:10.3390/genes14040785 · Cited by 3
Clinical homologous recombination repair gene reversion analysis identifies mechanisms of resistance to PARP inhibitors and platinum‐chemotherapy
Jia, Y., Yang, Q., Ma, Y., Wu, M., Ou, Q., Lin, Z., Wu, Y., & Li, J. (2024) · MedComm – Oncology · doi:10.1002/mog2.79 · Cited by 3
Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review)
Yu, H., & Wei, L. (2025) · Oncology Letters · doi:10.3892/ol.2025.14961 · Cited by 4
Genomics and molecular mechanisms of high grade serous ovarian cancer: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium
Rankin, E. B. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000490 · Cited by 3
The role of bacteria in the treatment of cancer: A comprehensive review
Khadem, E., Nafari, A., Safarzadeh, A., Jozaei, R. F., Almasian, M., & Elyasi, H. (2020) · Plant Biotechnology Persa · doi:10.29252/pbp.2.1.26 · Cited by 3
Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions
Rabban, J. T., Chen, L.-M., & Devine, W. P. (2022) · Surgical pathology clinics · doi:10.1016/j.path.2022.02.003 · Cited by 3
Prognostic and Predictive Biomarkers in Familial Breast Cancer
Deb, S., Chakrabarti, A., & Fox, S. B. (2023) · Cancers · doi:10.3390/cancers15041346 · Cited by 3
Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study)
Liontos, M., Timotheadou, E. T., Papadopoulos, E. I., Zafeiriou, Z., Lampropoulou, D. I., Aravantinos, G., Mavroudis, D., Christodoulou, C., Nikolaidi, A., Somarakis, A., et al. (2021) · Current Oncology · doi:10.3390/curroncol28060440 · Cited by 3
Targeted molecular profiling of epithelial ovarian cancer from Italian BRCA wild-type patients with a BRCA and PARP pathways gene panel
Salvati, A., Carnevali, I. W., Alexandrova, E., Facchi, S., Ronchi, S., Libera, L., Sahnane, N., Memoli, D., Lamberti, J., Amabile, S., et al. (2022) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2022.104833 · Cited by 3
Hereditary Ovarian Cancer
Sekine, M., & Enomoto, T. (2017) · Comprehensive gynecology and obstetrics · doi:10.1007/978-981-10-4160-0_2 · Cited by 3
Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma
Bernard, J., Mehros, W., Gregoire, J., Douville, P., Renaud, M., Sebastianelli, A., Langlais, E.-L., & Plante, M. (2022) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2022.06.005 · Cited by 2
Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse
Ma, Y., Liu, J., Li, N., Bu, H., Huang, Y., Jin, C., Wen, H., Feng, S., Zhang, H., Yang, X., et al. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01283-2 · Cited by 2
Development of Homologous Recombination Functional Assays for Targeting the DDR
Oswald, A. J., & Gourley, C. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_4 · Cited by 2
Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China
Feng, H., Zhao, L., Xu, Z., Xie, Q.-F., Deng, H., Jiang, Y., & Liu, H. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i5.102767 · Cited by 2
PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
Cánovas, M. S., Robles, J. L., Verdejo, F. J. G., Lavín, D. C., Olivares, H., Fernández, A. G., Coma, E., Verdúguez, T. Q., Coloma, C. S., Garay, D. F., et al. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04048-z · Cited by 2
Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance
McGehee, C. D., Meng, X. W., Wu, X., Correia, C., Venkatachalam, A., Flatten, K. S., Peterson, K. L., Patel, A. G., Rossman, O. K., Wong, C., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf990 · Cited by 2
Regulators of homologous recombination deficiency identified by machine learning using somatic multi-omics data
Valieris, R., Rosa, L. A. S., Martins, L. V. C., Defelicibus, A., Carraro, D. M., Nunes, D. N., Dias‐Neto, E., Rosales, R., & da Silva, I. T. (2025) · Life Science Alliance · doi:10.26508/lsa.202503531 · Cited by 2
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Criscuolo, D., Merolla, F., Pellegrino, B., Russolillo, L., Benedictis, I. D., Califano, D., Catalano, R., Baviello, C., Varricchio, S., Cecere, S. C., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0455 · Cited by 2
Real-world outcomes following PARP inhibitor maintenance in ovarian cancer by BRCA status: a retrospective cohort study
Zucker, K., Pickwell‐Smith, B., Samani, A., Sujenthiran, A., Pittell, H., Mpofu, P., & Hall, G. D. (2026) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100659 · Cited by 2
A Clinically Translatable Multimodal Deep Learning Model for HRD Detection from Histopathology Images
Uttarwar, M., Khandare, J. J., Shivamurthy, P. M., Satpute, A., Panwar, M., Kothavade, H., Ramesh, A., Iyer, S., & Shafi, G. (2026) · Diagnostics · doi:10.3390/diagnostics16020356 · Cited by 2
The mitochondrial translocation of phosphorylated EZH2 promotes PARP inhibitor resistance in BRCA1-deficient epithelial ovarian cancer
Hu, L., Ma, X., Cai, X., Yan, T., Zhou, K., Shan, C., Guo, N., Zheng, H., Wang, Y., Tong, Y., et al. (2026) · Cell Discovery · doi:10.1038/s41421-026-00880-x · Cited by 2
Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib
Latif, M. A. M., Mazhar, S., Tasleem, M., Alqurashi, A. A., Arfan, M., ‎, Z. A., & Zafar, M. B. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s575152 · Cited by 2
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program
Domènech, H., Simonetti, S., Romero-Lozano, P., Pettitt, S. J., Proszek, P., Viaplana, C., Smalley, M., Magraner-Pardo, L., García‐Galea, E., García-Durán, C., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01583-y · Cited by 2
The DNA damage response and cancer immunotherapy
Sheng, H., & Li, G. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00958-4 · Cited by 3

Authors: Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D.
Affiliations: Harvard University (US)
2Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Corresponding author: Konstantinopoulos, Panagiotis A.
ORCID: Konstantinopoulos, Panagiotis A.
Shapiro, Geoffrey I.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-11-01
Volume: 5
Issue: 11
Pages: 1137-1154
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-15-0714
PMC: PMC4631624
OpenAlex: W2179105349
Cited by: 945
References: 180
Citations by year: 2026: 67 · 2025: 97 · 2024: 109 · 2023: 126 · 2022: 115 · 2021: 102 · 2020: 100 · 2019: 74 · 2018: 74 · 2017: 54 · 2016: 27
FWCI: 5.56
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA090687, UM1CA186709, P50CA168504)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: homologous recombination deficiency, epithelial ovarian cancer, DNA repair deficiency, PARP inhibitors, synthetic lethality, platinum analogues, high-grade serous ovarian cancer, drug resistance, targeted therapy
MeSH terms: Carcinoma, Ovarian Epithelial, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, DNA Repair, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Phenotype, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Treatment Outcome, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks